About Affymetrix (NASDAQ:AFFX)
Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.
Industry, Sector and Symbol
Industry Bio Diagnostics & Testing
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio116.75
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity4.84%
Return on Assets2.97%
Affymetrix (NASDAQ:AFFX) Frequently Asked Questions
What is Affymetrix's stock symbol?
Affymetrix trades on the NASDAQ under the ticker symbol "AFFX."
How were Affymetrix's earnings last quarter?
Affymetrix, Inc. (NASDAQ:AFFX) announced its quarterly earnings data on Wednesday, February, 17th. The scientific and technical instruments company reported $0.09 EPS for the quarter, missing the Zacks' consensus estimate of $0.11 by $0.02. The scientific and technical instruments company earned $95.60 million during the quarter, compared to analyst estimates of $93.29 million. Affymetrix had a return on equity of 4.84% and a net margin of 4.24%. During the same quarter in the previous year, the business earned $0.09 earnings per share. View Affymetrix's Earnings History.
Who are some of Affymetrix's key competitors?
Some companies that are related to Affymetrix include Press Ganey (PGND), Aerie Pharmaceuticals (AERI), Teladoc (TDOC), Udg Healthcare (UDG), Primary Health Care (PRY), Cambrex (CBM), The Medicines (MDCO), Spectranetics (SPNC), Genus (GNS), Editas Medicine (EDIT), Clinigen Group (CLIN), Zai Lab (ZLAB), ProMetic Life Sciences (PLI), Neuroderm (NDRM), Sirtex Medical (SRX), Given Imaging (GIVN), National HealthCare (NHC) and Dynavax Technologies (DVAX).
How do I buy Affymetrix stock?
Shares of Affymetrix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affymetrix's stock price today?
One share of Affymetrix stock can currently be purchased for approximately $14.01.
How big of a company is Affymetrix?
Affymetrix has a market capitalization of $1.13 billion.
How can I contact Affymetrix?
Affymetrix's mailing address is 3420 Central Expy, SANTA CLARA, CA 95051-0703, United States. The scientific and technical instruments company can be reached via phone at +1-408-7315000.
MarketBeat Community Rating for Affymetrix (AFFX)MarketBeat's community ratings are surveys of what our community members think about Affymetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Affymetrix (NASDAQ:AFFX) Earnings History and Estimates Chart
Affymetrix (NASDAQ AFFX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/17/2016||Q415||$0.11||$0.09||$93.29 million||$95.60 million||View||N/A|
|10/28/2015||Q315||$0.08||$0.10||$88.04 million||$86.50 million||View||Listen|
|7/29/2015||Q215||$0.07||$0.12||$88.61 million||$89.00 million||View||Listen|
|4/29/2015||Q115||$0.04||$0.10||$87.30 million||$88.70 million||View||Listen|
|2/4/2015||Q414||$0.07||$0.09||$91.80 million||$93.50 million||View||Listen|
|10/30/2014||Q314||$0.04||$0.08||$84.40 million||$87.10 million||View||Listen|
|7/31/2014||Q214||$0.03||$0.07||$83.30 million||$85.40 million||View||Listen|
|5/1/2014||Q114||$0.02||$0.03||$81.10 million||$83.00 million||View||Listen|
|2/5/2014||Q413||$0.07||$0.02||$89.98 million||$92.60 million||View||Listen|
|7/31/2013||Q2 2013||($0.01)||$0.04||$78.53 million||$79.46 million||View||Listen|
|4/30/2013||Q1 2013||($0.02)||($0.01)||$78.04 million||$77.90 million||View||Listen|
|1/31/2013||Q4 2012||($0.03)||($0.02)||$84.06 million||$84.40 million||View||Listen|
|11/5/2012||Q312||($0.03)||($0.03)||$84.56 million||$79.60 million||View||N/A|
Affymetrix (NASDAQ:AFFX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Affymetrix (NASDAQ:AFFX)
No dividend announcements for this company have been tracked by MarketBeat.com
Affymetrix (NASDAQ AFFX) Insider Trading and Institutional Ownership History
Affymetrix (NASDAQ AFFX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2015||Robert H Trice||Director||Sell||2,500||$9.40||$23,500.00||47,278|| |
|11/17/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00||47,278|| |
|10/15/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00||47,278|| |
|7/20/2015||Frank Witney||CEO||Sell||37,991||$11.20||$425,499.20|| |
|7/10/2015||Frank Witney||CEO||Sell||62,756||$11.00||$690,316.00|| |
|6/26/2015||Frank Witney||CEO||Sell||75,000||$11.22||$841,500.00|| |
|6/22/2015||David A Weber||EVP||Sell||33,879||$12.00||$406,548.00|| |
|6/19/2015||David A Weber||EVP||Sell||14,760||$12.00||$177,120.00|| |
|6/4/2015||Frank Witney||CEO||Sell||75,000||$11.78||$883,500.00|| |
|2/17/2015||Gavin Wood||CFO||Sell||1,300||$11.40||$14,820.00|| |
|1/20/2015||Gavin Wood||CFO||Sell||22,500||$11.77||$264,825.00|| |
|1/12/2015||Gavin Wood||CFO||Sell||10,200||$10.77||$109,854.00|| |
|12/29/2014||Gavin Wood||CFO||Sell||18,734||$10.20||$191,086.80|| |
|11/19/2013||Robert Trice||Director||Sell||6,205||$7.98||$49,515.90||53,199|| |
|8/21/2012||Timothy C Barabe||CFO||Buy||10,000||$3.75||$37,500.00|| |
|8/17/2012||Timothy C Barabe||CFO||Buy||5,550||$3.99||$22,144.50|| |
|8/13/2012||Timothy C Barabe||CFO||Buy||4,450||$3.99||$17,755.50|| |
Affymetrix (NASDAQ AFFX) News Headlines
Affymetrix (NASDAQ:AFFX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Affymetrix (NASDAQ:AFFX) Income Statement, Balance Sheet and Cash Flow Statement
Affymetrix (NASDAQ AFFX) Stock Chart for Sunday, January, 21, 2018